Full-Time

Director GCO Program Lead

Updated on 9/3/2026

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$171.9k - $231.9k/yr

+ Annual Bonus Plan + Incentive Compensation Plan + Discretionary Equity Awards + Employee Stock Purchase Plan

Remote in USA

Remote

Remote within the United States.

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Risk Management
Data Analysis

Get referred to BeOne

See people who can refer or advise you

Requirements
  • Bachelor or higher degree in a scientific or healthcare discipline with 10+ years’ experience in clinical trial industry.
  • Travel might be required as per business need.
  • Project management exposure/experience across the entire lifecycle of multi-region/country clinical trials in a fast-paced global environment.
  • Experience across clinical program and study management, including ability to manage resources and timelines.
  • Continuous Improvement: Data Analysis, Issue Resolution, Quality Management, Regulatory Compliance, Root Cause Analysis, Schedule Management, Training.
  • Clinical Documentation and Records Management
  • Clinical Operations Management
  • Contract Management
  • Data Management
  • Feasibility Studies
  • Project / Program Design
  • Project / Program Management
  • Risk Management
  • Technical Reporting
  • Resource Management
  • Global Competencies such as Fosters Teamwork, Provides and Solicits Honest and Actionable Feedback, Self-Awareness, Acts Inclusively, Demonstrates Initiative, Entrepreneurial Mindset, Continuous Learning, Embraces Change, Results-Oriented, Analytical Thinking/Data Analysis, Financial Excellence, Communicates with Clarity
  • Microsoft Office
Responsibilities
  • Build, develop and retain the global team of gCSM, including hiring, training, mentoring, developing direct and indirect reports, performance appraisals and resource management.
  • Oversee the delivery and goal achievement of projects within the designated program(s), serving as the point of escalation for resolving issues that gCSM cannot resolve.
  • Collaborate with other GCPLs to define and implement strategies and key priorities across-programs, and establish global standards for goals, performance measures, and capability development for the gCSM roles.
  • GCO Representative for the designated program(s)
  • In coordination with Franchise Head, accountable to the Franchise ERC, DCT and other governance teams as appropriate as GCO representative, to provide clinical operational insight to drive the program strategy and ensure excellence in execution.
  • Lead/participate in the KOL engagement activities in the designated programs and may act as function spokesperson if needed.
  • Evaluate and develop strategic feasibility and budget estimates during Early Planning for new CDPs and upon strategy change during the conduct of a study, where needed.
  • Accountable for resource allocation and initiating CST formation; ensures appropriate transition of outputs from early planning to the gCSM.
  • Create and be accountable for the annual program budget and resource forecasts, as well as contributing to and tracking the relevant DCT goals for the program.
  • Create, review, and provide input to and maintain compound-level documents such as IB, DSUR, and protocol.
  • Oversee timely, quality, and efficient study planning and execution of associated studies within the allocated program.
  • Conduct regular program review meetings to mentor, support, and ensure all studies are tracking to the DCT/DRC-approved budget and timeline.
  • Report on study status, goals, and operational KPIs, and enforce quality KPIs with support from the Compliance team.
  • Collaborate with other GCPLs to evaluate and designate preferred global vendors and participate in vendor governance meetings.
  • Create or review performance and development plans for direct reports, facilitate and support delivery of performance and development goals.
  • Provide line management and mentorship to gCSMs working within the designated program(s).
  • Inspire and lead efforts to deepen scientific knowledge within the Clinical Operations’ function.
  • Champions a global mindset and approach across Clinical Operations to foster collaboration and consistency across the organization.
  • Provide expert knowledge on the execution of clinical trials through a deep understanding of ICH/GCP Guidelines and other applicable regulatory requirements.
  • Point of escalation for all compound-related issues.
  • Identify and drive process improvement initiatives in collaboration with Franchise Head and/or other GCPLs within program.
  • Collaborates with cross-functional leaders to provide operational perspectives to enable effective and efficient delivery of clinical development goals.
  • Travel might be required as per business need.
  • Supervisory Responsibilities: Line managing direct reports.
Desired Qualifications
  • Experience in both people management and program management preferred.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.

PR Newswire
Jul 21st, 2026
Seegene USA receives FDA emergency authorisation for first multiplex PCR test to diagnose viral causes of ulcerative skin lesions

Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.